MounjarovsOzempic

Mounjaro's active ingredient, tirzepatide, is a "dual agonist" that activates two gut-hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Most older drugs in this class hit only GLP-1. By stimulating both, tirzepatide prompts the pancreas to release insulin when blood sugar is high, lowers the glucagon hormone that raises blood sugar, slows how fast the stomach empties, and reduces appetite. The net effect is better blood-sugar control and, as a downstream benefit, significant weight loss. A built-in fatty-acid chain lets it bind to blood albumin, giving it a long half-life so it only needs to be injected once a week.

Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a natural gut hormone released after eating. It prompts the pancreas to release more insulin when blood sugar is high, suppresses glucagon (a hormone that raises blood sugar), and slows stomach emptying. It also acts on appetite centers in the brain to reduce hunger and food intake, which is why many people eat less and lose some weight.

In SURPASS-2, an open-label 40-week head-to-head trial of 1,879 adults with type 2 diabetes published in the New England Journal of Medicine (2021), tirzepatide beat injectable semaglutide 1 mg. In the primary (treatment-regimen) analysis, the 15 mg dose lowered A1C by about 2.30 percentage points and reduced body weight by roughly 11.2 kg (about 12% from a baseline near 94 kg), and the 5 mg dose lowered A1C by about 2.01 points with about 7.6 kg lost — versus 1.86 points and 5.7 kg with semaglutide. (In the secondary on-treatment analysis, 15 mg figures were larger, about 2.46 points and 12.4 kg.) About 60% of participants on 15 mg hit a combined target of A1C 6.5% or lower plus at least 10% weight loss, compared with 22% on semaglutide. In the separate SURPASS-CVOT outcomes trial (about 13,300 patients with type 2 diabetes and established atherosclerotic heart disease, ~4-year median follow-up, published in NEJM in 2025), tirzepatide was non-inferior to dulaglutide for major adverse cardiovascular events (HR 0.92) and showed a 16% lower rate of all-cause death (HR 0.84), alongside greater A1C and weight reductions. These trials were in people with type 2 diabetes; your results may differ.

Across the SUSTAIN clinical trial program, Ozempic lowered A1C by roughly 1.0 to 1.8 percentage points depending on dose and starting level, with average weight reductions of about 6 to 14 lb (roughly 2.5 to 6.5 kg) at the 0.5 mg and 1 mg doses, and more at 2 mg. In the SUSTAIN-6 cardiovascular outcomes trial (3,297 patients with type 2 diabetes at high cardiovascular risk, published in NEJM in 2016), semaglutide reduced the primary composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 26% versus placebo (6.6% vs 8.9%; hazard ratio 0.74, 95% CI 0.58 to 0.95). That composite benefit was driven mainly by a significant drop in nonfatal stroke; reductions in nonfatal heart attack and cardiovascular death individually were not statistically significant, and the trial notably found a higher rate of diabetic retinopathy complications in the semaglutide group. SUSTAIN-6 was designed as a safety (non-inferiority) trial that went on to show superiority on the composite. The separate 2024 FLOW trial showed a 24% reduction in a combined kidney-and-cardiovascular outcome, supporting the 2025 chronic kidney disease indication.

The most common side effects are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. These are usually mild to moderate, most pronounced when starting and after each dose increase, and tend to ease over days to weeks. Serious but less common risks include acute pancreatitis (severe, persistent stomach pain — seek care immediately), gallbladder problems and gallstones (more likely during rapid weight loss), severe low blood sugar especially when combined with insulin or sulfonylureas, kidney injury from dehydration due to vomiting or diarrhea, allergic reactions, and possible worsening of diabetic retinopathy. The boxed warning concerns thyroid C-cell tumors seen in rodents; whether this risk applies to humans is unknown, so watch for a neck lump, hoarseness, trouble swallowing, or persistent shortness of breath and tell your doctor. Report any severe or persistent symptoms to your prescriber.

The most common side effects (reported in at least 5% of patients) are gastrointestinal: nausea (about 16-20%), vomiting, diarrhea, abdominal pain, and constipation. These are usually worst early on or after a dose increase and often ease over time; eating smaller, lower-fat meals can help. Serious but less common risks include pancreatitis (severe, persistent abdominal pain), gallbladder problems, acute kidney injury from dehydration, low blood sugar (especially when combined with insulin or sulfonylureas), worsening diabetic retinopathy, and allergic reactions. Ozempic carries an FDA boxed warning because semaglutide caused thyroid C-cell tumors in rodents; whether it does so in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Tell your doctor about any persistent abdominal pain, vision changes, or signs of an allergic reaction.

As of 2026, Mounjaro's US list price is roughly $1,000-$1,080 for a one-month (four-pen) supply, with cash/retail prices often quoted between about $995 and $1,300 depending on pharmacy. With commercial insurance that covers Mounjaro for diabetes, Eli Lilly's Mounjaro Savings Card can drop the cost to as little as $25 per month (subject to a per-fill and annual cap). If you have commercial insurance that does NOT cover it, the savings card may bring it to as low as about $499/month. Federal rules bar manufacturer copay cards for people on Medicare, Medicaid, TRICARE, or VA. Medicare Part D may cover Mounjaro for type 2 diabetes (with formulary tier and prior-authorization rules) but does not cover GLP-1 drugs for weight loss. Off-label use for weight loss is increasingly denied by insurers. Confirm current pricing and your own coverage before starting.

As of 2026, Ozempic's list price (WAC) is roughly $935 per month, and retail cash prices at major pharmacies run about $935-$969 per month without insurance or discounts. Novo Nordisk's NovoCare direct self-pay program offers cash prices of about $349/month for the 0.25, 0.5, and 1 mg pens and about $499/month for the 2 mg pen, with an introductory offer near $199/month for some new patients on the 0.25 mg and 0.5 mg doses through June 30, 2026. Commercially insured patients with coverage may pay as little as $25/month using the manufacturer savings card, but that lowest pricing is capped (up to $100/month in savings, for a limited number of months) and excludes people with government insurance. Medicare and Medicaid typically cover Ozempic for diabetes (but not for off-label weight loss), and a Patient Assistance Program provides free medication to qualifying low-income, uninsured patients. GoodRx-style coupons usually trim the retail price only modestly. Confirm current pricing and your own coverage before starting.

Mounjaro is FDA-approved as an add-on to diet and exercise to improve blood sugar control in adults and pediatric patients 10 years and older with type 2 diabetes. It is NOT FDA-approved for weight loss or for type 1 diabetes. It should NOT be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — this is a boxed warning. Avoid or use with caution if you have a history of pancreatitis, severe gastrointestinal disease such as gastroparesis, diabetic retinopathy, or known hypersensitivity to tirzepatide. It is not recommended in pregnancy. Because delayed stomach emptying can reduce absorption of oral pills, Lilly advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after each dose increase. Discuss kidney issues and any history of gallbladder disease with your prescriber.

Ozempic is FDA-approved for adults with type 2 diabetes to improve blood sugar control, to reduce major adverse cardiovascular events in those who also have established cardiovascular disease, and (since January 2025, based on the FLOW trial) to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in those with type 2 diabetes and chronic kidney disease. It is not approved for type 1 diabetes or for weight loss on its own. Do NOT use it if you or a family member has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to semaglutide. Use caution with a history of pancreatitis, diabetic retinopathy, or gallbladder disease, and discuss pregnancy plans with your doctor. Your prescriber makes the final eligibility call.